TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24497658

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia and Pain (CBT-PI)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Pain (CBT-P)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Education-Only Control (EOC)
Number of subjects: 367
Study: 21098740

Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone induction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vincristine-adriamycin-dexamethasone
Number of subjects: 0
Study: 19179299

Group type: EXPERIMENTAL
Intervention: Valsartan (oral suspension, 2 mg/kg, max 80 mg)
Number of subjects: 26
Study: 17331241

Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Land exercises
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups (Hydrotherapy and Land exercises)
Number of subjects: 115
Study: 15390214

Group type: EXPERIMENTAL
Intervention: CCK‐4 (20 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11351143

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg o.a.d.
Number of subjects: 277

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 277
Study: 9039219

Group type: EXPERIMENTAL
Intervention: retinyl palmitate (200,000 IU per week for 1 year)
Number of subjects: 106

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 106
Study: 1565812

Group type: EXPERIMENTAL
Intervention: E2H9R9 regimen (ethambutol, isoniazid, rifampicin, pyrazinamide for 9 months)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Z2H9R9 regimen (ethambutol, isoniazid, rifampicin, pyrazinamide for 9 months)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Z2H6R6 regimen (ethambutol, isoniazid, rifampicin, pyrazinamide for 6 months)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 199
Study: 3909754

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 60

Group type: COMPARATOR
Intervention: meglumine iothalamate
Number of subjects: 60
Study: 30145365

Group type: EXPERIMENTAL
Intervention: Plasma PUFA levels (total, omega-3, omega-6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary PUFA intake (omega-6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined effects of antenatal vitamin D and early childhood PUFA
Number of subjects: 0
Study: 28657825

Group type: EXPERIMENTAL
Intervention: Tai Chi (12-week training regimen)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 37
Study: 26973167

Group type: EXPERIMENTAL
Intervention: Cortisol administration 40 min before extinction memory retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration 40 min before extinction memory retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 0
Study: 25226948

Group type: EXPERIMENTAL
Intervention: Four point weight bearing reduction system with a two‐belt treadmill, 40 minutes per day, 3 days per week for 4 weeks
Number of subjects: 20
Study: 22246479

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 85
Study: 20844543

Group type: EXPERIMENTAL
Intervention: Efonidipine-based regimen in strict-treatment group (target systolic BP <140 mm Hg)
Number of subjects: 4418

Group type: EXPERIMENTAL
Intervention: Efonidipine-based regimen in mild-treatment group (target systolic BP 140 to <160 mm Hg)
Number of subjects: 4418

Group type: EXPERIMENTAL
Intervention: Patients with baseline eGFR <60 ml min⁻¹ per 1.73 m²
Number of subjects: 4418

Group type: EXPERIMENTAL
Intervention: Patients with baseline eGFR ≥60 ml min⁻¹ per 1.73 m²
Number of subjects: 4418

Group type: EXPERIMENTAL
Intervention: Decline in eGFR
Number of subjects: 4418

Group type: EXPERIMENTAL
Intervention: Proteinuria at study entry
Number of subjects: 4418

Group type: EXPERIMENTAL
Intervention: Efonidipine-based regimens
Number of subjects: 4418
Study: 17715031

Group type: EXPERIMENTAL
Intervention: Esmolol (loading dose of 0.5 mg/kg in 30 ml normal saline over 5 min followed by an infusion of 50 microg.kg(‐1).min(‐1) until the end of surgery)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Esmolol (as above)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study: 16042670

Group type: EXPERIMENTAL
Intervention: Erythromycin 1200 mg day(‐1) for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12358953

Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide in oxygen
Number of subjects: 46

Group type: COMPARATOR
Intervention: 40% oxygen in air (control group)
Number of subjects: 46
Study: 10421302

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplementation
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 7668901

Group type: EXPERIMENTAL
Intervention: Increased total IgA RF in RA patients
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Increased IgA1 RF in RA patients
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Increased IgA2 RF in RA patients
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Increased concentrations of IgA RF and subclasses in RA patients with extraarticular manifestations
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Increased IgA RF subclasses in RA patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Increased IgA RF in non-rheumatic individuals
Number of subjects: 58
Study: 1761737

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil single doses of 100, 200, 400, 600, and 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil multiple doses of 100, 200, and 400 mg twice daily for 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (both single and multiple doses)
Number of subjects: 0
Study: 6625958

Group type: EXPERIMENTAL
Intervention: Active hemodialysis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham hemodialysis
Number of subjects: 24
Study: 30965389

Group type: EXPERIMENTAL
Intervention: Symptom-limited incremental cycle exercise test (Group A)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Resting on exercise bicycles (Group B)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Symptom-limited incremental cycle exercise test (Group C)
Number of subjects: 129
Study: 29912978

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 6430
Study: 26466136

Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (URT) on the dominant leg (DOM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 17
Study: 24564441

Group type: EXPERIMENTAL
Intervention: After Deployment, Adaptive Parenting Tools (ADAPT)
Number of subjects: 42
Study: 22207676

Group type: EXPERIMENTAL
Intervention: Duffy null (C/C genotype)
Number of subjects: 132

Group type: COMPARATOR
Intervention: C/T or T/T genotypes
Number of subjects: 132
Study: 19204593

Group type: EXPERIMENTAL
Intervention: Chronic physical training (8 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acute resistance exercise test (ARET)
Number of subjects: 14
Study: 17217442

Group type: EXPERIMENTAL
Intervention: XL/MMF
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: TAC/MMF
Number of subjects: 638

Group type: COMPARATOR
Intervention: CsA/MMF
Number of subjects: 638
Study: 15889519

Group type: EXPERIMENTAL
Intervention: Huanglian Fire‐Purging Mixture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Niuhuang Bolus for Lowering Blood Pressure
Number of subjects: 72
Study: 12364422

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride at 60 mg/d (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (1 tablet/d; group B)
Number of subjects: 100
Study: 9868651

Group type: EXPERIMENTAL
Intervention: 1 mg/(kg.d) liposomal amphotericin B (L‐AmB‐1)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 4 mg/(kg.d) liposomal amphotericin B (L‐AmB‐4)
Number of subjects: 87
Study: 8202100

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study: 3293408

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hygienic informational therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nondrug therapy (blood pressure responders)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hygienic therapy
Number of subjects: 0
Study: 31902431

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 742

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 742
Study: 31482337

Group type: EXPERIMENTAL
Intervention: 3D/3D image fusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2D/3D image fusion
Number of subjects: 32
Study: 28262280

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) approach
Number of subjects: 50
Study: 25423327

Group type: EXPERIMENTAL
Intervention: Magnesium oxide 800 mg daily
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Magnesium oxide 1200 mg daily
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 22980639

Group type: EXPERIMENTAL
Intervention: 350 μm fragmentation grids
Number of subjects: 160

Group type: COMPARATOR
Intervention: 500 μm fragmentation grids
Number of subjects: 160
Study: 20423926

Group type: EXPERIMENTAL
Intervention: Sleep extension (coached to increase sleep by at least 30-60 min/night)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison Group (maintains baseline sleep duration)
Number of subjects: 150
Study: 18663663

Group type: EXPERIMENTAL
Intervention: Serological biomarkers (pepsinogen I, pepsinogen II, gastrin-17, Helicobacter pylori antibodies)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Serological biomarkers in subgroups (normal stomachs, H. pylori non-atrophic gastritis, H. pylori-negative gastritis)
Number of subjects: 1000
Study: 15741837

Group type: EXPERIMENTAL
Intervention: Acute heavy resistance exercise protocol (AHREP) consisting of 6 sets of 10 repetition maximum parallel squats
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acute heavy resistance exercise protocol (AHREP)
Number of subjects: 19
Study: 12658930

Group type: EXPERIMENTAL
Intervention: Trimetazidine plus routine therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine therapy only
Number of subjects: 50
Study: 14528544

Group type: EXPERIMENTAL
Intervention: Feedback about fat intake
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Feedback for high fat consumers
Number of subjects: 118
Study: 7539890

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study: 2346354

Group type: EXPERIMENTAL
Intervention: Topical application of rifamycin SV
Number of subjects: 268

Group type: COMPARATOR
Intervention: Iodinated polyvidone dermal solution
Number of subjects: 268
Study: 400108

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (100 microgram four times daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 32
Study: 31501226

Group type: EXPERIMENTAL
Intervention: Participants with youth-onset T2D
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Participants with cardiac autonomic dysfunction
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Higher HbA1c over time
Number of subjects: 397
Study: 30942963

Group type: EXPERIMENTAL
Intervention: Waterpik® Water Flosser (WF) plus manual toothbrush
Number of subjects: 72

Group type: COMPARATOR
Intervention: Manual toothbrush (MT) alone
Number of subjects: 72
Study: 27217114

Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24650118

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic Clopidogrel
Number of subjects: 0
Study: 23100417

Group type: EXPERIMENTAL
Intervention: Decision threshold modulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging results
Number of subjects: 0
Study: 20618675

Group type: EXPERIMENTAL
Intervention: Chair‐type training machine for the elderly, 60‐min sessions twice a week for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 18363672

Group type: EXPERIMENTAL
Intervention: Weight-based ribavirin dosing (800-1400 mg/day) and PEG-IFN alfa-2b 1.5 microg/kg/week
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Weight-based ribavirin dosing (800-1400 mg/day) and PEG-IFN alfa-2b 1.0 microg/kg/week
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day
Number of subjects: 3000
Study: 15742451

Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 273

Group type: COMPARATOR
Intervention: Care-as-usual (Control)
Number of subjects: 273
Study: 12451365

Group type: EXPERIMENTAL
Intervention: Alefacept 7.5 mg
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study: 10519433

Group type: COMPARATOR
Intervention: Methylergometrine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 200
Study: 7547094

Group type: EXPERIMENTAL
Intervention: tenidap 120 mg day-1
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 2254678

Group type: EXPERIMENTAL
Intervention: Gingkco Biloba Extract (Tanakan)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7195230

Group type: EXPERIMENTAL
Intervention: AR-L 115 BS, 0.7 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dobutamine, 0.01 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30921340

Group type: EXPERIMENTAL
Intervention: DNA prime (ADVAX) and Modified Vaccine Ankara (MVA) boost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Homologous prime-boost regimen
Number of subjects: 0
Study: 28660370

Group type: EXPERIMENTAL
Intervention: Coverage restrictions in prescription drug plans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formulary generosity in prescription drug plans
Number of subjects: 0
Study: 25188815

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 25063041

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 2.7 g per day for 2 weeks
Number of subjects: 22
Study: 21849055

Group type: EXPERIMENTAL
Intervention: Usual care in combination with the particular tape technique
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care without the tape technique
Number of subjects: 140
Study: 19403556

Group type: EXPERIMENTAL
Intervention: Individualized self-management workbook intervention based on self-efficacy principles, duration 14 weeks.
Number of subjects: 10
Study: 18611341

Group type: EXPERIMENTAL
Intervention: 1,208 mmol/L (9%) KCl infusion
Number of subjects: 128

Group type: COMPARATOR
Intervention: 201 mmol/L (1.5%) potassium chloride infusion
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study: 16257627

Group type: EXPERIMENTAL
Intervention: Distance learning programme with educational materials
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group receiving mailed clinical guidelines on LUTS
Number of subjects: 187
Study: 12522323

Group type: COMPARATOR
Intervention: Orlistat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study: 9934752

Group type: EXPERIMENTAL
Intervention: FECOM
Number of subjects: 12

Group type: COMPARATOR
Intervention: barium paste
Number of subjects: 12
Study: 7652501

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g 8-hourly)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Ceftazidime (2 g 8-hourly)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 338

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Meropenem and Ceftazidime
Number of subjects: 338
Study: 1978026

Group type: EXPERIMENTAL
Intervention: IgG3 monoclonal antibody
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IgG1 monoclonal antibody
Number of subjects: 12

Group type: COMPARATOR
Intervention: Polyclonal anti-D
Number of subjects: 12
Study: 679941

Group type: EXPERIMENTAL
Intervention: Constant Resistance (CR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Variable Resistance (VR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36
Study: 31682266

Group type: EXPERIMENTAL
Intervention: 100 mg oral CBD
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vaporized CBD
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vaporized CBD-dominant cannabis (100 mg CBD; 3.7 mg ∆9-THC)
Number of subjects: 6
Study: 30840057

Group type: EXPERIMENTAL
Intervention: 270° posterior partial fundoplication (PF)
Number of subjects: 456

Group type: COMPARATOR
Intervention: 360° Nissen total fundoplication (TF)
Number of subjects: 456
Study: 28276290

Group type: EXPERIMENTAL
Intervention: Increased dietary energy density (ED) characterized by higher intake of extra virgin olive oil (EVOO) and nuts
Number of subjects: 4259

Group type: EXPERIMENTAL
Intervention: Lowest quintiles of ED change
Number of subjects: 4259

Group type: EXPERIMENTAL
Intervention: Highest quintile of ED change
Number of subjects: 4259

Group type: EXPERIMENTAL
Intervention: Increased intake of EVOO and nuts
Number of subjects: 4259

Group type: EXPERIMENTAL
Intervention: Decreased intake of other oils, vegetable and fruit consumption
Number of subjects: 4259
Study: 25338198

Group type: EXPERIMENTAL
Intervention: Direct-access online care
Number of subjects: 156

Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 156

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 156
Study: 23276124

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 344
Study: 21358487

Group type: EXPERIMENTAL
Intervention: Multicomponent pain and stress self-management group intervention (PASS)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Individually administered physical therapy (IAPT)
Number of subjects: 156
Study: 19671780

Group type: EXPERIMENTAL
Intervention: Frozen finger intervention using a water-filled ordinary rubber glove
Number of subjects: 100
Study: 17201801

Group type: EXPERIMENTAL
Intervention: Replacement-dose recombinant methionyl human leptin (r-metHuLeptin) during 72-hour fasting
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 72-hour fasting (without leptin administration)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Baseline fed state (control study)
Number of subjects: 6
Study: 15488878

Group type: EXPERIMENTAL
Intervention: Losartan 100mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: All ARBs (Losartan, Irbesartan, Candesartan)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 11226112

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 225

Group type: COMPARATOR
Intervention: Saline 2 mL
Number of subjects: 225
Study: 9773696

Group type: EXPERIMENTAL
Intervention: Paravertebral block of the ipsilateral nerve roots of T12, L1, and L2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Field block
Number of subjects: 30
Study: 8144341

Group type: EXPERIMENTAL
Intervention: Nonionic contrast media iohexol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ionic contrast media ioxaglate
Number of subjects: 20
Study: 3276279

Group type: EXPERIMENTAL
Intervention: Methyldopa (500 mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oxprenolol (80 mg/d)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methyldopa after switching from Oxprenolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oxprenolol after switching from Methyldopa
Number of subjects: 32
Study: 31657167

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with repetitive transcranial magnetic stimulation
Number of subjects: 220

Group type: COMPARATOR
Intervention: Rehabilitation training and repetitive transcranial magnetic stimulation (Control)
Number of subjects: 220
Study: 28279854

Group type: EXPERIMENTAL
Intervention: Goal-attainment-theory-based education program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine management (Control)
Number of subjects: 64
Study: 25413223

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 61
Study: 23305192

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 294
Study: 21777999

Group type: EXPERIMENTAL
Intervention: Prosthetic foot with decreased stiffness
Number of subjects: 12
Study: 18482454

Group type: EXPERIMENTAL
Intervention: 35 mg elemental iron (as ferrous fumarate) multivitamin
Number of subjects: 167

Group type: COMPARATOR
Intervention: 60 mg elemental iron (as ferrous sulphate) multivitamin
Number of subjects: 167
Study: 16169655

Group type: EXPERIMENTAL
Intervention: Commercially available composite surface sealers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentin-bonding agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Composite surface sealers
Number of subjects: 0